The Swiss System: Designed for Treatment, Not Health

In 2023, the total cost of the Swiss healthcare system reached CHF 93.95 billion, representing 11.7% of the nation’s Gross Domestic Product (GDP). This places Switzerland among the highest spenders in the OECD, second only to the United States in terms of per person expenditure. The OECD data indicates that Switzerland spends approximately USD 9,963 per capita on health, nearly double the OECD average of USD 5,967. While this high level of investment ensures that the Swiss population has access to cutting-edge medical technology and virtually no waiting lists for medical procedures, the allocation of these funds exposes a deep structural flaw: the system is reactive rather than proactive.

According to data from the Federal Statistical Office (FSO), of the nearly CHF 94 billion spent in 2023, only CHF 1.73 billion was allocated to "Prevention". This accounts to a mere 1.8% of total healthcare expenditures. This is not a temporary deviation but a structural pattern: prevention spending has stagnated between 1.7% and 2.1% of total health expenditure for over a decade.

This allocation is significantly lower than the OECD average of 3.4%, suggesting that Switzerland underinvests in prevention by nearly half compared to its economic peers. The consequences of this underinvestment are profound. In a system where nearly 98% of resources are directed toward curative, rehabilitative, and long-term care, the economic incentives are heavily skewed toward the treatment of disease rather than its avoidance. Furthermore, "Administration" costs alone consumed CHF 4.13 billion (4.4%) — more than double the amount spent on prevention. This administrative burden is a structural byproduct of the multi-payer system. It absorbs billions of francs without generating health outcomes, while evidence-based longevity interventions remain chronically underfunded.

It is often argued that prevention is difficult to measure and that many preventive interventions lack robust evidence. This concern is valid in the context of generic lifestyle advice or unstructured wellness programs. However, it does not apply to biomarker-driven, risk-stratified prevention, where outcomes can be objectively measured through longitudinal changes in metabolic, cardiovascular, musculoskeletal, and inflammatory markers. The persistence of low prevention spending in Switzerland therefore reflects not an evidence gap, but a misalignment between reimbursement structures and measurable health outcomes.

How The Impending Demographic Shift Threatens Sustainability

While the rising cost burden on private households already strains the current system, the demographic shift toward an ageing population pushes it toward structural unsustainability.

Life expectancy is increasing, yet the "health span" — the proportion of life spent in good health — is not. Demographic analysis by Deloitte projects a stark future for the Swiss dependency ratio. By 2050, the ratio of working-age people to pensioners is expected to drop to 2:1. This shift signals the arrival of the "Silver Economy," where a significant portion of the population will be over the age of 65. In advanced markets like Switzerland, the population aged 65 and older is projected to increase by 35% between 2025 and 2050.

This aging demographic drives costs not mainly through acute infectious diseases, but through the accumulation of Non-Communicable Diseases (NCDs) such as cardiovascular disease, diabetes, cancer, and neurodegenerative disorders. These conditions are largely manageable and, in many cases, preventable or delayable through early intervention and lifestyle modification. However, under the current "Sick Care" model, these conditions are treated only after symptoms manifest, leading to expensive, long-term dependency on the healthcare system.

The financial implications of maintaining the status quo are severe. Projections from Deloitte Switzerland indicate that without a structural reorientation, healthcare spending could nearly double from CHF 87 billion in 2019 to CHF 163.5 billion by 2040. A comprehensive pivot toward prevention and technological innovation could mitigate this rise, potentially saving the system CHF 30 billion annually by 2040, the study suggests. 

These savings would primarily be realized through reductions in therapy and rehabilitation costs. These sectors currently absorb billions of francs because patients are allowed to deteriorate to the point where intensive rehabilitation becomes necessary.  

The "Silver Economy" presents both a risk and an opportunity. Reinsurers like Swiss Re argue that the industry must evolve from "income replacement" models to "longevity management" solutions that integrate wealth and health planning. Yet, the rigidities of the mandatory health insurance system prevent the rapid adoption of these integrated solutions, leaving the Swiss population vulnerable to the rising costs of unchecked aging.  

The Burden on Families: The Decoupling of Wage and Premium

The macroeconomic inefficiency of the Swiss system is most acutely felt at the household level. The financing of the Swiss healthcare system is unique in that it relies heavily on per-capita premiums rather than income-based taxation. Every resident, regardless of wealth, pays the same premium for the same insurance policy within their region (though subsidies exist for the very poor).

This financing structure has led to a growing divergence between the cost of healthcare and the economic reality of Swiss families. The "premium burden" has become a central political and social issue. In 2024, nominal wages in Switzerland grew by 1.8%, but after accounting for inflation (1.1%), real wage growth was a meager 0.7%. In contrast, health insurance premiums for 2024 rose by 8.7%, for 2025 by another 6%, and for 2026 again 4.4%.

The following table shows the divergence of economic reality vs. healthcare costs (2024/2025):

The premium index has reached 222.9 points (more than doubling since 1999), while the wage index has barely moved past 110. This "decoupling" means that healthcare premiums are consuming an ever-larger share of household budgets. The Federal Statistical Office estimates that rising premiums directly reduced the growth of disposable income by 0.3 percentage points in 2025.

This financial squeeze creates a secondary barrier to longevity. As households are forced to allocate more "disposable" income to mandatory "Sick Care" premiums, they have less capital available to invest in out-of-pocket prevention strategies such as gym memberships, nutritional supplements, advanced diagnostics, or organic food, which are typically not covered by basic insurance. Thus, the rising cost of the mandatory system actively prevents private investment in preventative health, perpetuating a cycle of declining health status and rising costs.

To understand the drivers behind this development and the system’s resistance to change, we have to look at the incentive structure.

The Incentive Problem for Insurers

The Mechanics of Managed Competition

Switzerland’s healthcare system operates on the principle of “managed competition”. Residents are required to purchase basic health insurance (LAMal), but they are free to choose from over 50 private insurers. To ensure fairness, insurers cannot deny coverage based on pre-existing conditions, and they cannot profit from the basic insurance (it is a non-profit activity). Competition is theoretically designed to drive efficiency and lower prices.

However, the primary mechanism of competition is the annual premium. Insurers compete fiercely to offer the lowest monthly rate. This encourages policyholders to shop around and switch providers frequently. In 2025, following the sharp premium increases, the "churn rate" (switching rate) surged to 12%, which is significantly higher than the long-term average of 7.4%. In certain demographics, particularly young and urban populations, the consideration to switch went as high as 18%.

While this mobility keeps premiums somewhat in check, it introduces a fatal flaw regarding longevity: the "Churn Penalty".

The Churn Penalty

In a system where the average customer tenure is relatively short (often less than 8-10 years due to churn), insurers face an economic incentive regarding prevention. Longevity interventions like metabolic health programs, stress reduction coaching, or continuous glucose monitoring require an upfront investment. The Return on Investment (ROI) for these interventions, measured in avoided costs (e.g. avoided heart attacks, delayed onset of diabetes), typically accrues over a horizon of 10 to 20 years.

If an insurer invests CHF 2,000 today to improve the biological age of a 40-year-old client, that client becomes a more profitable risk in the future. However, given the 12% annual churn rate, there is a high statistical probability that by the time the client reaches the age where the savings materialize (e.g., age 55), they will have switched to a competitor.

The problem: Insurer A pays for the prevention, but Insurer B (the competitor) reaps the financial benefit of the healthier client. Insurer B, having not spent money on the prevention program, can afford to offer a slightly lower premium, thereby attracting the very client Insurer A invested in. This dynamic effectively punishes insurers who invest in long-term health and rewards those who run "bare-bones" operations focused solely on claims processing and risk selection.

As shown in Figure 2, high churn rates prevent insurers from capturing the long-term return on preventive investments, reinforcing short-term premium competition.

Opponents of longer-term insurance contracts frequently argue that annual switching is essential to protect consumer freedom. However, high churn rates come at a structural cost: they make long-term health investments economically irrational. Optional, capped multi-year contracts would not eliminate choice, but rather expand it by enabling insurers to offer differentiated products focused on long-term health outcomes rather than short-term premium competition.

Theoretical and empirical literature on health insurance markets confirms that high switching rates diminish the incentive for insurers to invest in "durable" health capital. In the Swiss context, where basic insurance covers almost no prevention by law, and supplementary insurance is volatile, this structural disincentive is a primary reason why prevention funding remains capped at 2%.

The Inadequacy of Risk Adjustment

To mitigate the risk of insurers "cherry-picking" only healthy clients, Switzerland has a risk adjustment scheme that transfers funds from insurers with healthier-than-average risk pools to those with sicker-than-average pools. This promotes equity, but it also inadvertently compounds the prevention problem.

Because the risk adjustment is largely based on morbidity criteria, such as previous hospitalizations and pharmaceutical cost groups, insurers are compensated for having sick patients. If an insurer successfully reverses a patient's chronic condition (e.g., putting Type 2 diabetes into remission through intensive lifestyle intervention), that patient may no longer trigger the high-risk payment from the adjustment pool and the insurer loses the subsidy.   

Equity concerns are often raised against health-linked incentives, with critics arguing that they may penalize individuals with chronic illness. This risk can be mitigated through careful design. Incentives should reward relative improvement rather than absolute health status. In such a framework, a patient who meaningfully improves metabolic or cardiovascular markers generates greater value than an already healthy individual who remains unchanged. Properly structured, prevention incentives can reduce inequality rather than reinforce it.

Current academic proposals suggest implementing "long-term risk adjustment" or multi-year contracts that would allow insurers to capture the value of health improvements. However, such reforms face political opposition under the banner of "consumer freedom", as they would restrict the citizen's right to change insurers annually.

The Tariff Trap

For over two decades, the Swiss outpatient sector has been governed by TARMED (Tarif Médical), a fee-for-service structure containing over 4,300 individual tariff positions. TARMED has been widely criticized for creating a “volume over value" incentive structure. Technical interventions are reimbursed at a higher rate relative to time spent than intellectual services like counseling, diagnostics, or preventative coaching.

This structure is fueling supply-induced demand. It is financially rational for a provider to perform a minor technical procedure instead of spending 45 minutes discussing sleep hygiene or nutritional strategies for longevity. The result is a system that is hyper-efficient at delivering interventions but inefficient at delivering health.

On January 1, 2026, TARMED has been replaced by a new tariff structure, TARDOC. This transition represents the most significant reform in Swiss billing in twenty years. The goal was to modernize the tariff, better value primary care, and reflect the reduced cost of technology.   

Unfortunately, the TARDOC structure reveals a potentially devastating impact on the "Longevity" agenda, specifically regarding preventative screening and diagnostics. Because TARDOC aims to correct the "overvaluation" of technical infrastructure, it imposes deep cuts on the reimbursement rates for radiology and diagnostic imaging. As a consequence, TARDOC in its current form, appears designed to save money on diagnostics today at the expense of treating advanced disease tomorrow.

Concerns about overdiagnosis and unnecessary anxiety from screening are legitimate, particularly when diagnostics are applied indiscriminately. However, longevity-oriented diagnostics are not intended as mass, one-off screenings, but as targeted, longitudinal tools applied to defined risk groups. When diagnostics are integrated into continuous care pathways, early detection reduces downstream costs rather than inflating them.

The Political Economy of Stasis: Lobbying and Legislation

The Swiss Parliament (Federal Assembly) is heavily influenced by interest groups representing the status quo. Data from Lobbywatch, a transparency organization, reveals the extent of these ties.

A significant number of parliamentarians in the committees responsible for health policy (such as the SGK - Commission for Social Security and Health) hold paid mandates on the boards of health insurers, hospital groups, and pharmaceutical companies. This creates a "vetocracy" where reforms that threaten the revenue streams of incumbents are systematically blocked or diluted.

The Insurer Lobby: Argues against expanding the basic benefit basket to include prevention, citing the need to control premium growth (despite premiums growing anyway).

The Provider Lobby: Resists global budgets or strict quality controls that would link payment to outcomes rather than volume.

The Pharma Lobby: While supportive of innovation, focuses lobbying on ensuring high reimbursement prices for drugs rather than structural system reform.

Case Study 1: The Failure of the Tobacco Advertising Ban

Switzerland’s tobacco policy illustrates how industry influence can override a clear public health mandate. Despite hosting the global or regional headquarters of major tobacco multinationals, Swiss voters approved a 2022 referendum to ban tobacco advertising that reaches children and adolescents.

Parliamentary implementation has since stalled, with center-right parties closely aligned with the tobacco lobby rejecting the Federal Council’s draft law in 2024 on grounds of economic freedom. As a result, Switzerland remains the only European country not to have ratified the WHO Framework Convention on Tobacco Control, demonstrating how even explicit popular votes for prevention can be neutralized by political and industry pressure.

Case Study 2: The Rejection of a Sugar Tax

A similar pattern appears in nutrition policy, despite non-communicable diseases such as obesity and diabetes being major cost drivers of the health system. Proposals for a sugar tax from several cantons and the Citizens’ Assembly, modeled on successful policies in countries like the UK, France, and Mexico, were rejected by Parliament in both 2021 and 2023.

Opposition, led by the retail and agri-food lobby, frames such measures as paternalistic and contrary to personal responsibility, creating a structural contradiction: the state avoids preventive fiscal tools in the name of freedom while socializing the resulting healthcare costs through mandatory insurance.

Together, these cases show how political gridlock systematically caps prevention spending and locks the system into a reactive “Sick Care” model rather than a longevity-oriented one.

It is frequently argued that Switzerland already operates one of the world’s best healthcare systems, and this claim is accurate in the context of acute and specialized care. However, excellence in treating disease does not automatically translate into excellence in preserving healthspan. The challenge facing Switzerland is not system quality, but system fitness for an ageing population dominated by non-communicable diseases.

The Innovation Export Phenomenon: Switzerland as Incubator, Not Adopter

Switzerland is home to one of the world's most vibrant life sciences ecosystems. Anchored by global giants like Roche and Novartis, and fueled by top-tier universities (ETH Zurich, EPFL), the country is a factory for biotech and longevity innovation. Yet, a peculiar phenomenon has emerged: "Innovation Export." Swiss-born startups, developing solutions that could solve domestic health challenges, are increasingly bypassing the Swiss market to launch first in the United States.

This is not merely a matter of market size; it is a function of regulatory arbitrage and market fragmentation.

The longevity industry often operates at the intersection of food and medicine — nutraceuticals, supplements, and postbiotics. Here, the regulatory divergence between Switzerland (aligned with the EU) and the US creates a massive barrier to domestic entry.

Case Study: Amazentis (Timeline Nutrition)

Amazentis, a spin-off from EPFL, developed "Mitopure" (Urolithin A), a proprietary postbiotic molecule clinically proven to enhance mitochondrial function and mitophagy—a key mechanism in aging.

The US Launch: To enter the US market, Amazentis utilized the GRAS (Generally Recognized As Safe) pathway. This mechanism allows a company to convene an independent panel of experts to review safety data. If the panel agrees, the company can notify the FDA. The FDA review is typically fast (months), and in Amazentis’s case, resulted in a "No Questions" letter. Timeline products launched in the US in 2020.

The Swiss/EU Barrier: In Switzerland and the EU, Urolithin A is classified as a Novel Food. This requires a centralized authorization procedure via the European Commission and a safety assessment by the European Food Safety Authority (EFSA). This process is rigorous, expensive, and notoriously slow, often taking 1.5 to 3 years.

The Result: A Swiss company, founded by Swiss scientists, manufactured in Switzerland, sold its longevity product to American consumers years before it could achieve widespread market penetration at home. The regulatory architecture of Europe effectively exported the health benefit of Swiss science to the US.

This pattern illustrates a broader paradox: Switzerland excels at generating longevity innovation, but its regulatory and reimbursement frameworks prevent rapid domestic adoption.

A similar dynamic afflicts the Medtech and Digital Health sectors.

Breakdown of the EU MRA: Following the breakdown of the Institutional Framework Agreement with the EU, Switzerland lost its Mutual Recognition Agreement (MRA) for medical devices. Swiss Medtech companies are now treated as "Third Country" manufacturers in the EU, requiring an Authorized Representative and facing higher bureaucratic hurdles.

US Pull Factors: Consequently, startups like Sopur and Aeon look West. The US offers a single market of 330 million people and established reimbursement codes for Digital Therapeutics.

Aeon's Preventative MRI: Aeon, a Zurich-based startup offering AI-driven full-body preventative MRI, has secured pilots with insurers like KPT. However, scaling such a service in Switzerland is hampered by the TARMED/TARDOC limitations discussed earlier — there is no tariff code for "preventative MRI" in basic insurance. In the US, the private-pay market for such services (e.g., Prenuvo) is booming, driven by a consumer base accustomed to out-of-pocket health spending.

Swissmedic vs. FDA

Benchmarking studies of regulatory agencies reveal that while Swissmedic is highly efficient in its scientific assessment (taking ~194 days), the overall time-to-market is often longer than the FDA due to administrative processes. The FDA's average approval time for new active substances is ~244 days, compared to Swissmedic's ~520 days (total time) in some years.

Regulatory caution plays an essential role in safeguarding patient safety. However, caution becomes counterproductive when it systematically delays access to interventions with strong safety profiles and clinical evidence. Fast-track pathways for well-characterized longevity interventions would not weaken regulatory standards, but rather align regulatory speed with scientific maturity.

The Path to Value-Based Healthcare (VBHC)

The consensus among health economists is that the only viable solution to the "Sick Care" crisis is Value-Based Healthcare (VBHC). This model shifts reimbursement from the volume of services (fee-for-service) to the value created for the patient (Outcome / Cost).

Critics of Value-Based Healthcare often cite its operational complexity, particularly the challenges of data integration and outcome measurement. While these challenges are real, existing Swiss pilot projects demonstrate that VBHC is technically feasible. We argue that the primary barrier is not feasibility, but the absence of interoperable data infrastructure and aligned incentives across providers.

In a VBHC model, providers are not paid for every scan or visit. Instead, they receive a bundled payment for managing a patient's condition over a cycle of care. This incentivizes prevention: if the provider keeps the patient healthy and avoids complications, they retain a higher margin. If the patient deteriorates and requires expensive rework, the provider bears the cost.

Switzerland has begun to experiment with VBHC, but implementation remains fragmented, existing as "islands of excellence" rather than systemic reform:

Roche / University Hospital Basel (USB): This flagship project implemented VBHC principles for lung cancer patients. By merging clinical data (outcomes) with the hospital's REKOLE cost accounting system, they successfully calculated the "cost per outcome" for specific patient cohorts. The study proved that VBHC is technically feasible in Switzerland but highlighted the immense difficulty of merging data silos.   

SwissDiabeter: Inspired by the successful Dutch "Diabeter" model, this initiative aims to create Integrated Practice Units (IPUs) for diabetes care. It proposes a bundled payment model where a multidisciplinary team (endocrinologist, nutritionist, psychologist) is paid a fixed fee to manage a diabetic patient. However, the current tariff law (TARMED/TARDOC) makes it legally difficult to bill such bundles across different provider types.   

Groupe Mutuel & Hôpital de La Tour: A private pilot project for hip and knee replacement surgery uses Patient-Reported Outcome Measures (PROMs) to assess quality and link payment to results. While innovative, it applies only to patients with specific supplementary insurance, limiting its population health impact.

A critical barrier to scaling VBHC is the lack of a unified, interoperable data infrastructure. The Electronic Patient Record (EPR/EPD) in Switzerland has been plagued by technical failures, low adoption rates, and a decentralized architecture (multiple "Stammgemeinschaften") that prevents data flow between regions.   

Without a seamless flow of data — tracking a patient from the GP to the hospital to the rehabilitation center — it is impossible to measure the "outcome" part of the value equation. You cannot pay for value if you cannot measure it.

Conclusion

Switzerland stands at a strategic inflection point. The country possesses all the ingredients required to become a global leader in longevity: world-class science, deep capital pools, high institutional trust, and a technologically advanced healthcare system. Yet these assets are currently assembled into a model that remains economically inefficient and structurally resistant to prevention.

The problem is not a lack of innovation or medical capability, but a misaligned incentive structure. The 2% prevention cap, the insurance churn penalty, the tariff logic of TARDOC, and entrenched political interests create a stable but suboptimal equilibrium. In this equilibrium, no single actor — insurer, provider, regulator, or politician — has sufficient incentive to move first. The rational strategy for each participant is to maintain the status quo, even though the collective outcome is worsening health outcomes and rising costs.

As a result, Switzerland increasingly functions as an incubator rather than an adopter of longevity innovation. Swiss science, startups, and intellectual property generate global value, while domestic patients remain locked in a reactive “Sick Care” system that intervenes late and expensively.

Breaking this equilibrium requires targeted structural interventions at four levels:

1. Align insurance incentives with long-term health outcomes
   Allow multi-year contracts in both basic and supplementary insurance, enabling insurers to capture the long-term return on preventive investments rather than losing it to competitors through churn.
2. Reform tariffs to reward prevention and early detection
   Adapt TARDOC to explicitly incentivize preventive services and diagnostics currently excluded from basic coverage, such as DEXA scans for osteoporosis or advanced imaging for early cancer detection.
3. Link economic rewards to measurable health improvements
   Legalize health dividends by allowing insurers to offer premium rebates not only for financial choices (e.g. high deductibles) but for verifiable biological improvements, such as reductions in biological age or sustained improvements in VO₂ max, funded by the long-term savings these improvements generate.
4. Accelerate regulatory pathways for proven longevity interventions
   Establish fast-track approval processes for longevity supplements and interventions that have already achieved FDA GRAS status or demonstrate strong clinical safety data from Swiss academic institutions.

Without these reforms, Switzerland will continue to pay ever-higher premiums for ever-later interventions. With them, it has the opportunity to transition from a system that manages decline to one that actively preserves health capital — and to lead globally in the economics of longevity.